Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access March 27, 2009

Antimicrobial resistance in bacteria

Katrijn Bockstael and Arthur Aerschot
From the journal Open Medicine


The development of antimicrobial resistance by bacteria is inevitable and is considered as a major problem in the treatment of bacterial infections in the hospital and in the community. Despite efforts to develop new therapeutics that interact with new targets, resistance has been reported even to these agents. In this review, an overview is given of the many therapeutic possibilities that exist for treatment of bacterial infections and how bacteria become resistant to these therapeutics.

[1] Cohen M.L., Changing patterns of infectious disease, Nature, 2000, 406, 762–767 in Google Scholar PubMed

[2] Yoneyama H., Katsumata R., Antibiotic resistance in bacteria and its future for novel antibiotic development, Biosci. Biotechnol. Biochem., 2006, 70, 1060–1075 in Google Scholar PubMed

[3] Wright G.D., Bacterial resistance to antibiotics: enzymatic degradation and modification, Adv. Drug Deliv. Rev., 2005, 57, 1451–1470 in Google Scholar PubMed

[4] Rachakonda S., Cartee L., Challenges in antimicrobial drug discovery and the potential of nucleoside antibiotics, Curr. Med. Chem., 2004, 11, 775–793 in Google Scholar PubMed

[5] Silver L.L., Novel inhibitors of bacterial cell wall synthesis, Curr. Opin. Microbiol., 2003, 6, 431–438 in Google Scholar PubMed

[6] Wise R., A review of the mechanisms of action and resistance of antimicrobial agents, Can. Respir. J., 1999, 6Suppl A, 20A–22A Search in Google Scholar

[7] Langton K.P., Henderson P.J., Herbert R.B., Antibiotic resistance: multidrug efflux proteins, a common transport mechanism?, Nat. Prod. Rep., 2005, 22, 439–451 in Google Scholar PubMed

[8] Lambert P.A., Bacterial resistance to antibiotics: modified target sites, Adv. Drug Deliv. Rev., 2005, 57, 1471–1485 in Google Scholar PubMed

[9] Kahne D., Leimkuhler C., Lu W., Walsh C., Glycopeptide and lipoglycopeptide antibiotics, Chem. Rev., 2005, 105, 425–448 in Google Scholar PubMed

[10] Reynolds P.E., Structure, biochemistry and mechanism of action of glycopeptide antibiotics, Eur. J. Clin. Microbiol. Infect. Dis., 1989, 8, 943–950 in Google Scholar PubMed

[11] Wilke M.S., Lovering A.L., Strynadka N.C., Betalactam antibiotic resistance: a current structural perspective, Curr. Opin. Microbiol., 2005, 8, 525–533 in Google Scholar PubMed

[12] Poole K., Resistance to beta-lactam antibiotics, Cell Mol. Life Sci., 2004, 61, 2200–2223 in Google Scholar

[13] Fisher J.F., Meroueh S.O., Mobashery S., Bacterial resistance to beta-lactam antibiotics: compelling opportunism, compelling opportunity, Chem. Rev., 2005, 105, 395–424 in Google Scholar

[14] Van Bambeke F., Van Laethem Y., Courvalin P., Tulkens P.M., Glycopeptide antibiotics: from conventional molecules to new derivatives, Drugs, 2004, 64, 913–936 in Google Scholar

[15] Williams D.H., The glycopeptide story—how to kill the deadly ’superbugs’, Nat. Prod. Rep., 1996, 13, 469–477 in Google Scholar

[16] Sussmuth R.D., Vancomycin resistance: small molecule approaches targeting the bacterial cell wall biosynthesis, Chembiochem., 2002, 3, 295–298<295::AID-CBIC295>3.0.CO;2-G10.1002/1439-7633(20020402)3:4<295::AID-CBIC295>3.0.CO;2-GSearch in Google Scholar

[17] Schmitz F.J., Higgins P.G., Mayer S., Fluit A.C., Dalhoff A., Activity of quinolones against Grampositive cocci: mechanisms of drug action and bacterial resistance, Eur. J. Clin. Microbiol. Infect. Dis., 2002, 21, 647–659 in Google Scholar

[18] Hooper D.C., Mechanisms of action of antimicrobials: focus on fluoroquinolones, Clin. Infect. Dis., 2001, 32Suppl 1, S9–S15 in Google Scholar

[19] Higgins P.G., Fluit A.C., Schmitz F.J., Fluoroquinolones: structure and target sites, Curr. Drug Targets., 2003, 4, 181–190 in Google Scholar

[20] Dougherty T.J., Beaulieu D., Barrett J.F., New quinolones and the impact on resistance, Drug Discov. Today, 2001, 6, 529–536 in Google Scholar

[21] Woodford N., Biological counterstrike: antibiotic resistance mechanisms of Gram-positive cocci, Clin. Microbiol. Infect., 2005, 11Suppl 3, 2–21 in Google Scholar

[22] Eliopoulos G.M., Quinolone resistance mechanisms in pneumococci, Clin. Infect. Dis., 2004, 38Suppl 4, S350–S356 10.1086/382709Search in Google Scholar

[23] Vannuffel P., Cocito C., Mechanism of action of streptogramins and macrolides, Drugs, 1996, 51Suppl 1, 20–30 in Google Scholar PubMed

[24] Johnston N.J., Mukhtar T.A., Wright G.D., Streptogramin antibiotics: mode of action and resistance, Curr. Drug Targets., 2002, 3, 335–344 in Google Scholar PubMed

[25] Shahid M., Aminoglycosidic aminocyclitol antibiotics-A wonder, but toxic drugs: Developments and clinical implications, Anti-infect. Agents Med. Chem., 2007, 6, 107–117 10.2174/187152107780361643Search in Google Scholar

[26] Jana S., Deb J.K., Molecular understanding of aminoglycoside action and resistance, Appl. Microbiol. Biotechnol., 2006, 70, 140–150 in Google Scholar PubMed

[27] Kotra L.P., Haddad J., Mobashery S., Aminoglycosides: perspectives on mechanisms of action and resistance and strategies to counter resistance, Antimicrob. Agents Chemother., 2000, 44, 3249–3256 in Google Scholar PubMed PubMed Central

[28] Speer B.S., Shoemaker N.B., Salyers A.A., Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance, Clin. Microbiol. Rev., 1992, 5, 387–399 10.1128/CMR.5.4.387Search in Google Scholar PubMed PubMed Central

[29] Roberts M.C., Update on acquired tetracycline resistance genes, FEMS Microbiol. Lett., 2005, 245, 195–203 in Google Scholar PubMed

[30] Chopra I., Roberts M., Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance, Microbiol. Mol. Biol. Rev., 2001, 65, 232–260 in Google Scholar PubMed PubMed Central

[31] Maravic G., Macrolide resistance based on the Ermmediated rRNA methylation, Curr. Drug Targets. Infect. Disord., 2004, 4, 193–202 in Google Scholar PubMed

[32] Weisblum B., Erythromycin resistance by ribosome modification, Antimicrob. Agents Chemother., 1995, 39, 577–585 10.1128/AAC.39.3.577Search in Google Scholar PubMed PubMed Central

[33] Rezanka T., Spizek J., Sigler K., Medicinal use of lincosamides and microbial resistance to them, Anti-infect. Agents Med. Chem., 2007, 6, 133–144 10.2174/187152107780361670Search in Google Scholar

[34] Bozdogan B., Appelbaum P.C., Oxazolidinones: activity, mode of action, and mechanism of resistance, Int. J. Antimicrob. Agents, 2004, 23, 113–119 in Google Scholar PubMed

[35] Toh S.M., Xiong L., Arias C.A., Villegas M.V., Lolans K., Quinn J., Mankin A.S., Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid, Mol. Microbiol., 2007, 64, 1506–1514 in Google Scholar PubMed PubMed Central

[36] Enoch D.A., Bygott J.M., Daly M.L., Karas J.A., Daptomycin, J. Infect., 2007, 55, 205–213 in Google Scholar PubMed

[37] Johnson A., Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria, Future. Microbiol., 2006, 1, 255–265 in Google Scholar PubMed

[38] Lange R.P., Locher H.H., Wyss P.C., Then R.L., The targets of currently used antibacterial agents: lessons for drug discovery, Curr. Pharm. Des, 2007, 13, 3140–3154 in Google Scholar PubMed

Published Online: 2009-3-27
Published in Print: 2009-6-1

© 2009 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Scroll Up Arrow